Literature DB >> 2897845

Exact localization of the familial dysbetalipoproteinemia associated HpaI restriction site in the promoter region of the APOC1 gene.

M Smit1, E van der Kooij-Meijs, L P Woudt, L M Havekes, R R Frants.   

Abstract

An HpaI restriction fragment length polymorphism (RFLP) in the APOE-C1-C2 gene cluster on chromosome 19 is strongly associated with familial dysbetalipoproteinemia (type III hyperlipoproteinemia). Recently we localized this polymorphic HpaI site between the APOE and APOC1 genes. In the present paper we show by molecular cloning and sequencing that the polymorphic HpaI site is located 317 bp upstream of the transcription initiation site of the APOC1 gene. Overlapping cosmid clones allowed the construction of a detailed restriction map of the gene cluster, showing the APOC2 gene to be located 15 kb downstream of the APOC1 pseudogene.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897845     DOI: 10.1016/s0006-291x(88)80424-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl.

Authors:  N S Shachter; T Ebara; R Ramakrishnan; G Steiner; J L Breslow; H N Ginsberg; J D Smith
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

2.  Human ApoCI HpaI restriction site polymorphism revealed by the polymerase chain reaction.

Authors:  W M Nillesen; H J Smeets; B A van Oost
Journal:  Nucleic Acids Res       Date:  1990-06-11       Impact factor: 16.971

3.  Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice.

Authors:  N S Shachter; T Hayek; T Leff; J D Smith; D W Rosenberg; A Walsh; R Ramakrishnan; I J Goldberg; H N Ginsberg; J L Breslow
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

4.  Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.

Authors:  P de Knijff; A M van den Maagdenberg; D I Boomsma; A F Stalenhoef; A H Smelt; J J Kastelein; A D Marais; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

5.  APOC1 T45S polymorphism is associated with reduced obesity indices and lower plasma concentrations of leptin and apolipoprotein C-I in aboriginal Canadians.

Authors:  Piya Lahiry; Henian Cao; Matthew R Ban; Rebecca L Pollex; Mary Mamakeesick; Bernard Zinman; Stewart B Harris; Anthony J G Hanley; Murray W Huff; Philip W Connelly; Robert A Hegele
Journal:  J Lipid Res       Date:  2009-10-06       Impact factor: 5.922

6.  Evidence for a dominant gene that suppresses hypercholesterolemia in a family with defective low density lipoprotein receptors.

Authors:  H H Hobbs; E Leitersdorf; C C Leffert; D R Cryer; M S Brown; J L Goldstein
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

7.  WAT apoC-I secretion: role in delayed chylomicron clearance in vivo and ex vivo in WAT in obese subjects.

Authors:  Yannick Cyr; Hanny Wassef; Simon Bissonnette; Valerie Lamantia; Jean Davignon; May Faraj
Journal:  J Lipid Res       Date:  2016-04-03       Impact factor: 5.922

8.  ApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African Americans.

Authors:  Erdembileg Anuurad; Masayuki Yamasaki; Neil Shachter; Thomas A Pearson; Lars Berglund
Journal:  J Lipid Res       Date:  2009-02-27       Impact factor: 5.922

9.  An improved RSP method to detect HpaI polymorphism in the apolipoprotein C-1 gene promoter.

Authors:  Li Gao; Curt Gabriel; Tera Lavoie; Shui Qing Ye
Journal:  BMC Med Genet       Date:  2002-11-12       Impact factor: 2.103

10.  Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1.

Authors:  Nicole E B Skinner; Matthew S Wroblewski; Julie A Kirihara; Gary L Nelsestuen; Elizabeth R Seaquist
Journal:  Diabetes Ther       Date:  2015-07-22       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.